JP2010510214A - Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 - Google Patents
Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 Download PDFInfo
- Publication number
- JP2010510214A JP2010510214A JP2009537198A JP2009537198A JP2010510214A JP 2010510214 A JP2010510214 A JP 2010510214A JP 2009537198 A JP2009537198 A JP 2009537198A JP 2009537198 A JP2009537198 A JP 2009537198A JP 2010510214 A JP2010510214 A JP 2010510214A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- bcl
- compound
- leukemia
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C(N1*C1)=O)P Chemical compound C*(C(N1*C1)=O)P 0.000 description 11
- DCODLJYDEORGSQ-XUSKOWTRSA-N CC(C)C[C@@H](CN1CCCC1)N(Cc1cc(CN2OC(CO)[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2C(C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1O Chemical compound CC(C)C[C@@H](CN1CCCC1)N(Cc1cc(CN2OC(CO)[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2C(C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1O DCODLJYDEORGSQ-XUSKOWTRSA-N 0.000 description 1
- FXJKXQQMEYALMP-VYMGZEJASA-N CC(C)C[C@@H](CN1CCCC1)N(Cc1cc(CN2O[C@@H](CO)[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1OCC(O)=O Chemical compound CC(C)C[C@@H](CN1CCCC1)N(Cc1cc(CN2O[C@@H](CO)[C@@H]([C@H](C)O)[C@H]2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(cccc1)c1OCC(O)=O FXJKXQQMEYALMP-VYMGZEJASA-N 0.000 description 1
- JWLLFUPJRKQPTB-YWHUUSLISA-N CC(C)C[C@@H](CN1CCCC1)N(Cc1cc(CN[C@@H]([C@H]([C@H](C)O)[C@H](CO)OC)C2(C3C2C3)N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)ccc1)Cc(cccc1)c1OCCO Chemical compound CC(C)C[C@@H](CN1CCCC1)N(Cc1cc(CN[C@@H]([C@H]([C@H](C)O)[C@H](CO)OC)C2(C3C2C3)N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)ccc1)Cc(cccc1)c1OCCO JWLLFUPJRKQPTB-YWHUUSLISA-N 0.000 description 1
- KOQUQCSYRMQRGD-ZNMPQEOVSA-N CC(C)[C@@H](CN(C)C)N(Cc1cc(CN2O[C@@H](CO)[C@@H]([C@H](C)O)C2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(c(F)ccc1)c1Cl Chemical compound CC(C)[C@@H](CN(C)C)N(Cc1cc(CN2O[C@@H](CO)[C@@H]([C@H](C)O)C2C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)ccc1)Cc(c(F)ccc1)c1Cl KOQUQCSYRMQRGD-ZNMPQEOVSA-N 0.000 description 1
- FVDFBSFSODEVBF-CRLOLVOASA-N CCOc1cccc(CN(Cc2cc(CN3OC(CO)[C@@H]([C@H](C)O)C3C(N[C@@H]3[C@@H](C)[C@H](C4)C(C)(C)[C@H]4C3)=O)ccc2)[C@@H](CC(C)C)CN(C)C)c1O Chemical compound CCOc1cccc(CN(Cc2cc(CN3OC(CO)[C@@H]([C@H](C)O)C3C(N[C@@H]3[C@@H](C)[C@H](C4)C(C)(C)[C@H]4C3)=O)ccc2)[C@@H](CC(C)C)CN(C)C)c1O FVDFBSFSODEVBF-CRLOLVOASA-N 0.000 description 1
- CWTOCJRIRQRMQK-UHFFFAOYSA-N CN(C)CNC(C1CCCCC1)c(cccc1)c1F Chemical compound CN(C)CNC(C1CCCCC1)c(cccc1)c1F CWTOCJRIRQRMQK-UHFFFAOYSA-N 0.000 description 1
- SCVLEUUEXXFVBW-GYGZLAGMSA-N C[C@@H]([C@H]1C(C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(CN(Cc(c(F)ccc3)c3Cl)[C@H](CN(C)C)C=C)c2)O[C@H]1CO)O Chemical compound C[C@@H]([C@H]1C(C(N[C@@H]2[C@@H](C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(CN(Cc(c(F)ccc3)c3Cl)[C@H](CN(C)C)C=C)c2)O[C@H]1CO)O SCVLEUUEXXFVBW-GYGZLAGMSA-N 0.000 description 1
- IPZWQMKRZXHYKW-VIHRGTOWSA-N C[C@@H]([C@H]1[C@@H](C(N[C@@H]2C(C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(CN(CCN(C)C)C(C3CCCCC3)c3ccccc3)c2)OC1CO)O Chemical compound C[C@@H]([C@H]1[C@@H](C(N[C@@H]2C(C)[C@H](C3)C(C)(C)[C@H]3C2)=O)N(Cc2cccc(CN(CCN(C)C)C(C3CCCCC3)c3ccccc3)c2)OC1CO)O IPZWQMKRZXHYKW-VIHRGTOWSA-N 0.000 description 1
- LKEUABCSWZLASW-HFXXUHSDSA-N C[C@@H]1C(C)[C@H](C2)C(C)(C)[C@H]2C1 Chemical compound C[C@@H]1C(C)[C@H](C2)C(C)(C)[C@H]2C1 LKEUABCSWZLASW-HFXXUHSDSA-N 0.000 description 1
- LKEUABCSWZLASW-JXUBOQSCSA-N C[C@@H]1[C@@H](C)[C@H](C2)C(C)(C)[C@H]2C1 Chemical compound C[C@@H]1[C@@H](C)[C@H](C2)C(C)(C)[C@H]2C1 LKEUABCSWZLASW-JXUBOQSCSA-N 0.000 description 1
- XOKSLPVRUOBDEW-VGMNWLOBSA-N C[C@H]1[C@H](C2)C(C)(C)[C@H]2CC1 Chemical compound C[C@H]1[C@H](C2)C(C)(C)[C@H]2CC1 XOKSLPVRUOBDEW-VGMNWLOBSA-N 0.000 description 1
- KQMXPHISFRKBJP-UHFFFAOYSA-N Nc1c2OCOc2ccc1 Chemical compound Nc1c2OCOc2ccc1 KQMXPHISFRKBJP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/600,332 US7842815B2 (en) | 2004-06-17 | 2006-11-15 | Compounds and methods for inhibiting the interaction of BCL proteins with binding partners |
| PCT/US2007/023941 WO2008060569A1 (en) | 2006-11-15 | 2007-11-14 | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230960A Division JP2014055156A (ja) | 2006-11-15 | 2013-11-07 | Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010510214A true JP2010510214A (ja) | 2010-04-02 |
| JP2010510214A5 JP2010510214A5 (enExample) | 2011-01-06 |
Family
ID=39064388
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009537198A Pending JP2010510214A (ja) | 2006-11-15 | 2007-11-14 | Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 |
| JP2013230960A Pending JP2014055156A (ja) | 2006-11-15 | 2013-11-07 | Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013230960A Pending JP2014055156A (ja) | 2006-11-15 | 2013-11-07 | Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7842815B2 (enExample) |
| EP (1) | EP2094673B1 (enExample) |
| JP (2) | JP2010510214A (enExample) |
| KR (1) | KR101530721B1 (enExample) |
| CN (1) | CN101583606B (enExample) |
| AU (1) | AU2007319848B2 (enExample) |
| BR (1) | BRPI0718606A2 (enExample) |
| CA (1) | CA2669596C (enExample) |
| EC (1) | ECSP099398A (enExample) |
| ES (1) | ES2537762T3 (enExample) |
| GT (1) | GT200900123A (enExample) |
| IL (1) | IL198597A (enExample) |
| MA (1) | MA31067B1 (enExample) |
| MX (1) | MX2009005184A (enExample) |
| MY (1) | MY156754A (enExample) |
| NO (1) | NO20092306L (enExample) |
| NZ (1) | NZ577243A (enExample) |
| RU (1) | RU2449996C2 (enExample) |
| TN (1) | TN2009000182A1 (enExample) |
| WO (1) | WO2008060569A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| KR20160061439A (ko) | 2007-03-28 | 2016-05-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 스티칭된 폴리펩티드 |
| CA2714251C (en) * | 2008-02-08 | 2017-08-15 | Aileron Therapeutics, Inc. | Therapeutic peptidomimetic macrocycles |
| US8314250B2 (en) * | 2009-11-24 | 2012-11-20 | Hoffmann-La Roche Inc. | Sultam derivatives |
| JP6342808B2 (ja) | 2011-10-18 | 2018-06-13 | エイルロン セラピューティクス，インコーポレイテッド | ペプチドミメティック大環状化合物 |
| WO2013119579A1 (en) | 2012-02-06 | 2013-08-15 | Discoveryx Corporation | Detection of intracellular binding events by measuring protein abundance |
| EP3769776A1 (en) | 2012-02-15 | 2021-01-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| CN108912211A (zh) | 2012-02-15 | 2018-11-30 | 爱勒让治疗公司 | 三唑交联的和硫醚交联的拟肽大环化合物 |
| CN103656642A (zh) * | 2012-08-31 | 2014-03-26 | 中国科学院上海生命科学研究院 | 预防和治疗结直肠癌的方法和试剂 |
| WO2014078014A2 (en) | 2012-11-14 | 2014-05-22 | Metabolix, Inc. | Production of salts of 4-hydroxybutyrate using biobased raw materials |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| EP3099380B1 (en) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CN108368161A (zh) | 2015-09-10 | 2018-08-03 | 艾瑞朗医疗公司 | 作为mcl-1调节剂的拟肽大环化合物 |
| IL312398A (en) | 2016-03-28 | 2024-06-01 | Presage Biosciences Inc | Pharmaceutical combinations for cancer treatment |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| WO2017197051A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Amine-linked c3-glutarimide degronimers for target protein degradation |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| MA48027B1 (fr) * | 2017-04-05 | 2022-12-30 | Harvard College | Composé macrocyclique et utilisations de celui-ci |
| CN118440096A (zh) | 2017-06-20 | 2024-08-06 | C4医药公司 | 用于蛋白降解的n/o-连接的降解决定子和降解决定子体 |
| CN120698983A (zh) | 2018-12-20 | 2025-09-26 | C4医药公司 | 靶向蛋白降解 |
| WO2021233948A1 (en) | 2020-05-19 | 2021-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to treat a pathogen lung infection |
| EP4175644A1 (en) | 2020-07-06 | 2023-05-10 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml) |
| WO2025087879A2 (en) | 2023-10-23 | 2025-05-01 | Institut National de la Santé et de la Recherche Médicale | Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009907A2 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
| WO2006009869A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| WO2007075387A1 (en) * | 2005-12-16 | 2007-07-05 | Infinity Discovery, Inc. | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| JPS55133364A (en) | 1979-04-03 | 1980-10-17 | Mitsubishi Petrochem Co Ltd | Preparation of isoxazolidine derivative |
| DE3643012A1 (de) | 1986-12-17 | 1988-06-30 | Hoechst Ag | 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung |
| CA2083179C (en) | 1990-05-18 | 2001-10-23 | Robert Ryder Bartlett | Isoxazole-4-carboxamides and hydroxyalkylidenecyanoacetamides, pharmaceuticals containing these compounds and their use |
| US5294617A (en) * | 1993-04-23 | 1994-03-15 | American Cyanamid Company | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
| DK0623615T3 (da) * | 1993-05-01 | 1999-12-13 | Merck Patent Gmbh | Adhæsionsreceptor-antagonister |
| JPH09505590A (ja) | 1993-11-24 | 1997-06-03 | ザ・デュポン・メルク・ファーマシュウティカル・カンパニー | 新規なイソオキサゾリンおよびイソオキサゾールフィブリノーゲン受容体拮抗剤 |
| FI963510A7 (fi) | 1994-03-09 | 1996-09-06 | Pfizer | Isoksatsoliiniyhdisteitä TNF:n vapautumisen inhibiittoreina |
| US5514505A (en) * | 1995-05-15 | 1996-05-07 | Xerox Corporation | Method for obtaining improved image contrast in migration imaging members |
| DE19539638A1 (de) | 1995-10-25 | 1997-04-30 | Hoechst Ag | Die Verwendung von Isoxazol- und Crotonsäureamidderivaten zur Behandlung von Krebserkrankungen |
| US6221865B1 (en) * | 1995-11-06 | 2001-04-24 | University Of Pittsburgh | Inhibitors of protein isoprenyl transferases |
| ATE230392T1 (de) | 1996-08-16 | 2003-01-15 | Bristol Myers Squibb Pharma Co | Amidinophenyl-pyrrolidine, -pyrroline und - isoxazolidine und ihre derivate |
| AU5239198A (en) | 1996-10-16 | 1998-05-11 | President And Fellows Of Harvard College, The | Droplet assay system |
| CA2288330C (en) | 1997-05-07 | 2014-02-11 | University Of Pittsburgh | Benzoyl amino acid derivatives useful as inhibitors of protein isoprenyl tranferases |
| WO2001016115A1 (en) | 1999-09-01 | 2001-03-08 | Chemrx Advanced Technologies, Inc. | Process for synthesizing isoxazolidines |
| KR100399361B1 (ko) * | 1999-11-04 | 2003-09-26 | 주식회사 엘지생명과학 | 캐스파제 억제제 함유 치료제 조성물 |
| US20030008924A1 (en) | 2001-05-30 | 2003-01-09 | The Regents Of The University Of Michigan | Small molecule antagonists of Bcl-2 family proteins |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide |
-
2006
- 2006-11-15 US US11/600,332 patent/US7842815B2/en not_active Expired - Fee Related
-
2007
- 2007-11-14 BR BRPI0718606-1A patent/BRPI0718606A2/pt not_active IP Right Cessation
- 2007-11-14 WO PCT/US2007/023941 patent/WO2008060569A1/en not_active Ceased
- 2007-11-14 RU RU2009121808/04A patent/RU2449996C2/ru not_active IP Right Cessation
- 2007-11-14 EP EP07840052.0A patent/EP2094673B1/en active Active
- 2007-11-14 ES ES07840052.0T patent/ES2537762T3/es active Active
- 2007-11-14 JP JP2009537198A patent/JP2010510214A/ja active Pending
- 2007-11-14 AU AU2007319848A patent/AU2007319848B2/en not_active Ceased
- 2007-11-14 CN CN200780049702.7A patent/CN101583606B/zh not_active Expired - Fee Related
- 2007-11-14 NZ NZ577243A patent/NZ577243A/en not_active IP Right Cessation
- 2007-11-14 MY MYPI20091840A patent/MY156754A/en unknown
- 2007-11-14 CA CA2669596A patent/CA2669596C/en not_active Expired - Fee Related
- 2007-11-14 KR KR1020097012239A patent/KR101530721B1/ko not_active Expired - Fee Related
- 2007-11-14 MX MX2009005184A patent/MX2009005184A/es active IP Right Grant
-
2009
- 2009-05-06 IL IL198597A patent/IL198597A/en not_active IP Right Cessation
- 2009-05-08 TN TNP2009000182A patent/TN2009000182A1/fr unknown
- 2009-05-12 GT GT200900123A patent/GT200900123A/es unknown
- 2009-06-09 EC EC2009009398A patent/ECSP099398A/es unknown
- 2009-06-10 MA MA31972A patent/MA31067B1/fr unknown
- 2009-06-15 NO NO20092306A patent/NO20092306L/no not_active Application Discontinuation
-
2010
- 2010-11-30 US US12/956,969 patent/US8461191B2/en not_active Expired - Fee Related
-
2013
- 2013-11-07 JP JP2013230960A patent/JP2014055156A/ja active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006009907A2 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Isoxazolidine compounds for treatment of bacterial infections |
| WO2006009869A1 (en) * | 2004-06-17 | 2006-01-26 | Infinity Pharmaceuticals, Inc. | Coumpounds and methods for inhibiting the interaction of bcl proteins with binding partners |
| WO2007075387A1 (en) * | 2005-12-16 | 2007-07-05 | Infinity Discovery, Inc. | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110160259A1 (en) | 2011-06-30 |
| ECSP099398A (es) | 2009-07-31 |
| KR20090082284A (ko) | 2009-07-29 |
| HK1130057A1 (en) | 2009-12-18 |
| AU2007319848A1 (en) | 2008-05-22 |
| IL198597A (en) | 2014-03-31 |
| IL198597A0 (en) | 2010-02-17 |
| EP2094673A1 (en) | 2009-09-02 |
| CA2669596A1 (en) | 2008-05-22 |
| ES2537762T3 (es) | 2015-06-11 |
| TN2009000182A1 (en) | 2010-10-18 |
| GT200900123A (es) | 2011-09-02 |
| NZ577243A (en) | 2011-12-22 |
| CN101583606A (zh) | 2009-11-18 |
| KR101530721B1 (ko) | 2015-06-22 |
| US20070161690A1 (en) | 2007-07-12 |
| EP2094673B1 (en) | 2015-04-08 |
| JP2014055156A (ja) | 2014-03-27 |
| AU2007319848B2 (en) | 2012-05-03 |
| US20080306127A9 (en) | 2008-12-11 |
| MX2009005184A (es) | 2009-10-12 |
| CN101583606B (zh) | 2015-04-08 |
| NO20092306L (no) | 2009-08-17 |
| MA31067B1 (fr) | 2010-01-04 |
| US7842815B2 (en) | 2010-11-30 |
| CA2669596C (en) | 2014-09-30 |
| WO2008060569A1 (en) | 2008-05-22 |
| US8461191B2 (en) | 2013-06-11 |
| RU2009121808A (ru) | 2010-12-20 |
| RU2449996C2 (ru) | 2012-05-10 |
| BRPI0718606A2 (pt) | 2013-12-17 |
| MY156754A (en) | 2016-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014055156A (ja) | Ｂｃｌタンパクの結合パートナーとの相互作用を阻害するための化合物および方法 | |
| RU2416606C2 (ru) | Соединения и способы для ингибирования взаимодействия bcl белков с компонентами по связыванию | |
| ES2489645T3 (es) | Compuestos y métodos para inhibir la interacción de proteínas BLC con compañeros de unión | |
| JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
| HK1130057B (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners | |
| HK1105963B (en) | Compounds and methods for inhibiting the interaction of bcl proteins with binding partners |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101111 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101111 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121211 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130308 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131107 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131218 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140124 |